Search
Search filters
Type
Audience
Category
Issue
Last updated
- 20231 results available
- 20222 results available
- 20218 results available
- 20191 results available
- 20181 results available
- 20162 results available
- 20151 results available
- 20141 results available
- 20131 results available
- 20124 results available
- 20092 results available
- 20074 results available
- 20065 results available
- 20057 results available
- 20044 results available
- 20032 results available
- 20025 results available
- 20011 results available
Recall class
Displaying 1 - 15 of 52 items.
Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines
AlertPublic advisory | 2021-11-09
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
AlertHealth professional risk communication | 2021-06-29
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
AlertHealth professional risk communication | 2021-03-24
Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-03-01
Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-Labelled Supply)
AlertHealth professional risk communication | 2021-03-31
Authorization of COVISHIELD with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-03-01
Adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine
AlertPublic advisory | 2021-03-11
Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines
AlertPublic advisory | 2021-06-29
Archived - For the Public - Important Safety Information on IRESSA (gefitinib) - AstraZeneca Canada Inc.
AlertHealth professional risk communication | 2007-05-14
Archived - Important Safety Information on IRESSA® (gefitinib) 250 mg Tablets - AstraZeneca Canada Inc.
AlertInformation update | 2005-08-26
Archived – Important Safety Information Regarding Accolate® (Zafirlukast) and Hepatic Effects – AstraZeneca
AlertHealth professional risk communication | 2002-12-18
Important Safety Information on Oxeze (formoterol fumarate dihydrate) Turbuhaler – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-09-09
Association of CRESTOR® (rosuvastatin) with Muscle -Related Adverse Events – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-03-11
Archived - Public Advisory: Liver Problems Associated With Use of ACCOLATE (zafirlukast) in Some Patients - AstraZeneca - For the Public
AlertHealth professional risk communication | 2002-12-18
Archived – Important Safety Information Concerning Liver Problems for Patients Taking ACCOLATE® (Zafirlukast) – AstraZeneca Canada Inc. – For the Public
AlertHealth professional risk communication | 2004-04-19